[go: up one dir, main page]

TN2009000487A1 - Triazol compounds for treating biofilm formation - Google Patents

Triazol compounds for treating biofilm formation

Info

Publication number
TN2009000487A1
TN2009000487A1 TNP2009000487A TN2009000487A TN2009000487A1 TN 2009000487 A1 TN2009000487 A1 TN 2009000487A1 TN P2009000487 A TNP2009000487 A TN P2009000487A TN 2009000487 A TN2009000487 A TN 2009000487A TN 2009000487 A1 TN2009000487 A1 TN 2009000487A1
Authority
TN
Tunisia
Prior art keywords
biofilm formation
triazol
treating biofilm
triazol compounds
compounds
Prior art date
Application number
TNP2009000487A
Other languages
English (en)
Inventor
David Reid
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38534753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000487(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2009000487A1 publication Critical patent/TN2009000487A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TNP2009000487A 2007-05-22 2009-11-20 Triazol compounds for treating biofilm formation TN2009000487A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07108650A EP1994930A1 (fr) 2007-05-22 2007-05-22 Compositions de triazole pour traiter la formation de biofilm
PCT/EP2008/056231 WO2008142094A1 (fr) 2007-05-22 2008-05-21 Utilisation d'un composé i pour prévenir ou traiter une formation de biofilm

Publications (1)

Publication Number Publication Date
TN2009000487A1 true TN2009000487A1 (en) 2011-03-31

Family

ID=38534753

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000487A TN2009000487A1 (en) 2007-05-22 2009-11-20 Triazol compounds for treating biofilm formation

Country Status (18)

Country Link
US (2) US8309590B2 (fr)
EP (3) EP1994930A1 (fr)
JP (1) JP5470245B2 (fr)
KR (1) KR101519675B1 (fr)
CN (2) CN101678004A (fr)
AU (1) AU2008252964B2 (fr)
BR (1) BRPI0811103A2 (fr)
CA (1) CA2685112A1 (fr)
CL (1) CL2008001469A1 (fr)
IL (1) IL201832A (fr)
MA (1) MA31388B1 (fr)
MX (1) MX2009012628A (fr)
NZ (1) NZ580735A (fr)
RU (1) RU2478385C2 (fr)
TN (1) TN2009000487A1 (fr)
TW (1) TWI419690B (fr)
WO (1) WO2008142094A1 (fr)
ZA (1) ZA200907415B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
US20090227647A1 (en) 2008-03-05 2009-09-10 Thomas Lake Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
JP5548121B2 (ja) 2007-05-14 2014-07-16 リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク バイオフィルム中の細菌細胞における生理学的分散応答の誘導
EP1994930A1 (fr) * 2007-05-22 2008-11-26 Novartis AG Compositions de triazole pour traiter la formation de biofilm
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition
TWI415572B (zh) 2011-06-17 2013-11-21 Univ Chang Gung 利用１，２，３，４，６－五－ｏ－沒食子醯基－ｄ－葡哌喃糖來抑制生物膜形成
US10028933B2 (en) * 2015-07-22 2018-07-24 Ohio State Innovation Foundation Compositions and methods for inhibiting the growth of multi-drug resistant microbes
RU2646488C2 (ru) * 2016-04-25 2018-03-05 Государственное бюджетное образовательное учреждение высшего профессионального образования "Оренбургский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ОрГМУ Минздрава России) Средство для селективного влияния на биопленкообразование микроорганизмами
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CN110448693A (zh) * 2019-07-30 2019-11-15 华东理工大学 氟喹诺酮类药物作为多粘菌素类抗生素增敏剂的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004438A (en) * 1991-12-31 1999-12-21 3M Innovative Properties Company Biofilm reduction sterilizer
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
WO1997049397A1 (fr) * 1996-06-26 1997-12-31 Sankyo Company, Limited Nouvelles compositions medicinales d'hydropyridines
US6759040B1 (en) * 1997-09-12 2004-07-06 University Of Maryland, College Park Preparation and use of biofilm-degrading, multiple-specificity, hydrolytic enzyme mixtures
AU2001256965A1 (en) * 2000-03-23 2001-10-03 Influx, Inc. Bactericidal antimicrobial methods and compositions for use in treating gram positive infections comprising an antibiotic potentiator having acyl hydrazide oxy amide or 8-hydroxy quinoline structure
WO2002076439A2 (fr) * 2001-03-23 2002-10-03 The Board Of Trustees Of The University Of Illinois Composes capables de moduler l'activite de transporteurs de medicaments multiples et leur utilisation therapeutique
GB0126618D0 (en) * 2001-11-06 2002-01-02 Novartis Ag Organic compounds
GB0205593D0 (en) * 2002-03-09 2002-04-24 Univ Nottingham Treatment of surfaces populated by bacteria
US20040043052A1 (en) * 2002-05-24 2004-03-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for coating medical implants
US7498292B2 (en) 2002-08-15 2009-03-03 The Research Foundation Of State University Of New York Combinatorial libraries of autoinducer analogs, autoinducer agonists and antagonists, and methods of use thereof
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
EP1994930A1 (fr) * 2007-05-22 2008-11-26 Novartis AG Compositions de triazole pour traiter la formation de biofilm

Also Published As

Publication number Publication date
RU2478385C2 (ru) 2013-04-10
CN103381271A (zh) 2013-11-06
TWI419690B (zh) 2013-12-21
IL201832A0 (en) 2010-06-16
BRPI0811103A2 (pt) 2014-12-09
AU2008252964B2 (en) 2011-12-01
NZ580735A (en) 2012-02-24
CL2008001469A1 (es) 2010-10-29
CA2685112A1 (fr) 2008-11-27
JP5470245B2 (ja) 2014-04-16
KR101519675B1 (ko) 2015-05-12
ZA200907415B (en) 2010-07-28
EP1994930A1 (fr) 2008-11-26
RU2009147297A (ru) 2011-06-27
IL201832A (en) 2015-11-30
EP2253317A3 (fr) 2011-03-16
US20120329746A1 (en) 2012-12-27
TW200913996A (en) 2009-04-01
US8592473B2 (en) 2013-11-26
US8309590B2 (en) 2012-11-13
EP2162130A1 (fr) 2010-03-17
CN101678004A (zh) 2010-03-24
AU2008252964A1 (en) 2008-11-27
MA31388B1 (fr) 2010-05-03
JP2010527960A (ja) 2010-08-19
US20100152101A1 (en) 2010-06-17
WO2008142094A4 (fr) 2009-01-29
WO2008142094A1 (fr) 2008-11-27
EP2253317A2 (fr) 2010-11-24
KR20100017153A (ko) 2010-02-16
MX2009012628A (es) 2009-12-07

Similar Documents

Publication Publication Date Title
TN2009000487A1 (en) Triazol compounds for treating biofilm formation
WO2003063864A3 (fr) Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
NO20085060L (no) Triazolpyrazinderivater anvendelige som anti-cancermidler
IL205152A0 (en) 1, 2, 3 - triazole derivatives for use as stearoyl - coa desaturase inhibitors
NZ595035A (en) Substituted diazole and triazole compounds and compositions and methods of use
MX2009012163A (es) Hetarilanilinas como moduladores para beta-amiloide.
WO2008020040A3 (fr) Utilisation de composés et de dérivés de 2,5-dihydroxybenzène pour le traitement de la fibrose
SG159388A1 (en) Antibacterial agents
WO2007066189A3 (fr) Sels, promedicaments et formulations de 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-uree
WO2010032147A3 (fr) Dérivés d'acide hydroxamique utiles comme agents antibactériens
NO20062689L (no) Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer
JP2010515715A5 (fr)
WO2005044192A3 (fr) Composes triazole et utilisations associees
NO20082496L (no) Pyrazinderivater
WO2009120660A3 (fr) Pyridoxazines substituées
WO2008151288A3 (fr) Composés aromatiques et hétéroaromatiques utiles dans le traitement de troubles du métabolisme du fer
WO2010115184A3 (fr) Hydroxylthiénoquinolones et composés apparentés utilisables en tant qu'agents anti-infectieux
GB0710121D0 (en) Antifungal agents
TW200603841A (en) Dispersible tablets comprising a benzoic acid derivative
NO20065061L (no) Benzoksazin for behandling av sykdommer i luftveiene
NO20084913L (no) Sammensetning inneholdende en jernchelator og et anti-neoplatisk middel og anvendelse derav
MX2009005619A (es) Formas poliformicas del deferasirox (icl670a).
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2006051314A8 (fr) Composes chimiques
NO20090193L (no) Substituerte heterocykliske etere og anvendelse derav i CNS forstyrrelser